Loading clinical trials...
Loading clinical trials...
Effectiveness and Safety of Therapy Based on Attenuated Arsenic Trioxide Plus Low Doses of All-trans Retinoic Acid as Remission Induction Therapy in Patients With Acute Promyelocytic Leukemia Phase 1/2 Clinical Trial
Conditions
Interventions
Arsenic trioxide
all-trans retinoic acid
Locations
1
Mexico
Hopsital Universitario Dr. Jose E. Gonzalez, Centro Universitario contra el Cancer
Monterrey, Nuevo León, Mexico
Start Date
July 1, 2022
Primary Completion Date
June 30, 2025
Completion Date
July 31, 2025
Last Updated
October 26, 2022
NCT00003861
NCT03624270
NCT04251754
NCT02899169
NCT03096496
NCT01445080
Lead Sponsor
Hospital Universitario Dr. Jose E. Gonzalez
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions